Continuing Trastuzumab After Progression Shows Promise in HER2+ Gastric/GEJ Cancer
(MedPage Today) -- Continuing trastuzumab (Herceptin)-containing therapy beyond progression led to encouraging progression-free survival (PFS) and overall survival (OS) rates in advanced HER2-positive gastric/gastroesophageal junction (GEJ) cancer...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin